Provided by Tiger Trade Technology Pte. Ltd.

Blackline Inc.

29.77
+0.52001.78%
Post-market: 29.70-0.0700-0.24%19:35 EDT
Volume:881.56K
Turnover:26.13M
Market Cap:1.73B
PE:52.89
High:29.93
Open:29.38
Low:29.29
Close:29.25
52wk High:59.57
52wk Low:24.70
Shares:58.13M
Float Shares:44.10M
Volume Ratio:1.07
T/O Rate:2.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.5629
EPS(LYR):0.3900
ROE:7.03%
ROA:1.64%
PB:5.47
PE(LYR):76.33

Loading ...

Blackline Inc : Morgan Stanley Cuts to Equal-weight from Overweight

THOMSON REUTERS
·
Jul 21

Blackline Cut to Equal-weight from Overweight by Morgan Stanley

Dow Jones
·
Jul 21

Morgan Stanley Downgrades BlackLine to Equalweight From Overweight, Adjusts PT to $33 From $50

MT Newswires Live
·
Jul 21

U.S. Research Roundup-colgate-palmolive, IBM, Unitedhealth

Reuters
·
Jul 21

BlackLine (BL) Opens Birmingham Office On Growth Narrative That Still Points To Undervaluation

Simply Wall St.
·
Jul 21

BIOKIN Pharmaceutical Receives Regulatory Approval for Esophageal Cancer Treatment with Novel Antibody-Drug Conjugate

Stock News
·
Jul 16

Does BlackLine’s New Birmingham Hub Reveal a Deeper Shift in Its Innovation Strategy (BL)?

Simply Wall St.
·
Jul 16

Analysts Conflicted on These Technology Names: PDF Solutions (PDFS) and BlackLine (BL)

TIPRANKS
·
Jul 10

Blackline Opens New Birmingham Office at 10 Brindleyplace

Reuters
·
Jul 09

AI Governance Push With New Finance Control Console Could Be A Game Changer For BlackLine (BL)

Simply Wall St.
·
Jul 09

LegalZoom Stock And 2 Compliance Software Picks For Trump Tariff Uncertainty

Simply Wall St.
·
Jul 07

BlackLine (BL) Could Be 29% Undervalued After Its AI Finance Control Launch

Simply Wall St.
·
Jul 04

BlackLine Launches Finance Control Console to Govern AI-Powered Operations

MT Newswires Live
·
Jun 25

BIOKIN's Novel Dual-Antibody Drug Receives Marketing Approval in China

Stock News
·
Jun 22

UBS Adjusts Price Target on BlackLine to $430 From $380, Maintains Neutral Rating

MT Newswires Live
·
Jun 18

BlackLine (BL) Stock Could Be 32.7% Undervalued After Mixed Earnings Signals

Simply Wall St.
·
Jun 17

Biokin Pharma Gets Nod to Trial BL-M14D1 With Other Therapies

MT Newswires Live
·
Jun 15

Blackline Safety FY26 Q2 net loss narrows 16% to CAD 3.13 million; revenue rises 23% to CAD 44.29 million

Reuters
·
Jun 10

Blackline director Mika Yamamoto sells 3,000 shares for $85,426

Reuters
·
Jun 09

BIOKIN Receives FDA Green Light for Phase 3 Trial of BL-M14D1 in Front-Line Extensive-Stage Small Cell Lung Cancer

Stock News
·
Jun 08